Literature DB >> 10395842

A canarypox vaccine expressing multiple human immunodeficiency virus type 1 genes given alone or with rgp120 elicits broad and durable CD8+ cytotoxic T lymphocyte responses in seronegative volunteers.

T G Evans1, M C Keefer, K J Weinhold, M Wolff, D Montefiori, G J Gorse, B S Graham, M J McElrath, M L Clements-Mann, M J Mulligan, P Fast, M C Walker, J L Excler, A M Duliege, J Tartaglia.   

Abstract

Induction of CD8+ cytotoxic T cells is considered one of the important correlates for the protective efficacy of candidate human immunodeficiency virus type 1 (HIV-1) vaccines. To induce CD8+ cytotoxic T lymphocytes (CTLs) along with neutralizing antibody and CD4+ T cell help, a live canarypox virus construct expressing gp120, transmembrane gp41, the gag and protease genes, and sequences containing CTL epitopes in nef and pol was given simultaneously with, or followed by, rgp120 SF2. CD8+ CTLs were detected in 61% of volunteers at some time during the trial. Three to 6 months after the last immunization, the gene-specific responses were gag, 26/81; env, 17/77; nef, 12/77; and pol, 3/16. Simultaneous immunization with the canarypox vector and the subunit, beginning with the initial immunization, resulted in earlier antibody responses. In summary, a strategy of immunization with a canarypox vector expressing multiple genes of HIV-1 given with gp120 results in durable CD8+ CTL responses to a broad range of epitopes.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10395842     DOI: 10.1086/314895

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  44 in total

1.  Prior vaccination increases the epitopic breadth of the cytotoxic T-lymphocyte response that evolves in rhesus monkeys following a simian-human immunodeficiency virus infection.

Authors:  Sampa Santra; Dan H Barouch; Marcelo J Kuroda; Jörn E Schmitz; Georgia R Krivulka; Kristin Beaudry; Carol I Lord; Michelle A Lifton; Linda S Wyatt; Bernard Moss; Vanessa M Hirsch; Norman L Letvin
Journal:  J Virol       Date:  2002-06       Impact factor: 5.103

2.  A human immunodeficiency virus prime-boost immunization regimen in humans induces antibodies that show interclade cross-reactivity and neutralize several X4-, R5-, and dualtropic clade B and C primary isolates.

Authors:  F Verrier; S Burda; R Belshe; A M Duliege; J L Excler; M Klein; S Zolla-Pazner
Journal:  J Virol       Date:  2000-11       Impact factor: 5.103

3.  A significant number of human immunodeficiency virus epitope-specific cytotoxic T lymphocytes detected by tetramer binding do not produce gamma interferon.

Authors:  P A Goepfert; A Bansal; B H Edwards; G D Ritter; I Tellez; S A McPherson; S Sabbaj; M J Mulligan
Journal:  J Virol       Date:  2000-11       Impact factor: 5.103

Review 4.  Strategies for an HIV vaccine.

Authors:  Norman L Letvin
Journal:  J Clin Invest       Date:  2002-07       Impact factor: 14.808

Review 5.  The development and use of vaccine adjuvants.

Authors:  Robert Edelman
Journal:  Mol Biotechnol       Date:  2002-06       Impact factor: 2.695

Review 6.  Challenges in the search for an HIV vaccine.

Authors:  Angelique A C Lemckert; Jaap Goudsmit; Dan H Barouch
Journal:  Eur J Epidemiol       Date:  2004       Impact factor: 8.082

Review 7.  Aiming to induce broadly reactive neutralizing antibody responses with HIV-1 vaccine candidates.

Authors:  Barton F Haynes; David C Montefiori
Journal:  Expert Rev Vaccines       Date:  2006-06       Impact factor: 5.217

8.  The Thai Phase III HIV Type 1 Vaccine trial (RV144) regimen induces antibodies that target conserved regions within the V2 loop of gp120.

Authors:  Nicos Karasavvas; Erik Billings; Mangala Rao; Constance Williams; Susan Zolla-Pazner; Robert T Bailer; Richard A Koup; Sirinan Madnote; Duangnapa Arworn; Xiaoying Shen; Georgia D Tomaras; Jeffrey R Currier; Mike Jiang; Craig Magaret; Charla Andrews; Raphael Gottardo; Peter Gilbert; Timothy J Cardozo; Supachai Rerks-Ngarm; Sorachai Nitayaphan; Punnee Pitisuttithum; Jaranit Kaewkungwal; Robert Paris; Kelli Greene; Hongmei Gao; Sanjay Gurunathan; Jim Tartaglia; Faruk Sinangil; Bette T Korber; David C Montefiori; John R Mascola; Merlin L Robb; Barton F Haynes; Viseth Ngauy; Nelson L Michael; Jerome H Kim; Mark S de Souza
Journal:  AIDS Res Hum Retroviruses       Date:  2012-10-04       Impact factor: 2.205

9.  Magnitude and frequency of cytotoxic T-lymphocyte responses: identification of immunodominant regions of human immunodeficiency virus type 1 subtype C.

Authors:  V Novitsky; H Cao; N Rybak; P Gilbert; M F McLane; S Gaolekwe; T Peter; I Thior; T Ndung'u; R Marlink; T H Lee; M Essex
Journal:  J Virol       Date:  2002-10       Impact factor: 5.103

Review 10.  DNA vaccines against human immunodeficiency virus type 1 in the past decade.

Authors:  Malavika Giri; Kenneth E Ugen; David B Weiner
Journal:  Clin Microbiol Rev       Date:  2004-04       Impact factor: 26.132

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.